Home » Regions » Asia » ShangPharma acquires Charles River’s Shanghai facility

ShangPharma acquires Charles River’s Shanghai facility

Monday, October 24, 2011

ShangPharma, a China-based pharmaceutical and biotechnology research and development outsourcing company, has acquired the assets in Charles River Laboratories International’s Shanghai research facility.

As part of the transaction, ShangPharma will take over Charles River’s lease for the facility, which will provide the company with an additional 2,972 square meters (31,990 square feet) of in-vivo research facilities originally designed for GLP Tox studies, and 1,290 square meters (13,885 square feet) of lab and office space.

Kevin Chen, ShangPharma’s president and chief operating officer, commented, “This transaction nearly triples ShangPharma’s overall research model production and research capacity, positioning us to further leverage China’s advantages in the area of in-vivo studies. The location of this facility within ShangPharma’s main research campus is a notable strategic advantage, helping us to achieve significant operating efficiencies through consolidation with our current facilities.”

Financial terms of the deal, which is subject to customary closing conditions, were not announced.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!